• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity).

作者信息

Stevenson Lauren, Amaravadi Lakshmi, Myler Heather, Salazar-Fontana Laura, Gorovits Boris, Kirshner Susan, Xue Li, Garofolo Fabio, Alley Stephen C, Thway Theingi, Joyce Alison, Bansal Surendra, Beaver Chris, Bergeron Annik, Cai Xiao-Yan, Cojocaru Laura, DeSilva Binodh, Dumont Isabelle, Fluhler Eric, Fraser Stephanie, Gouty Dominique, Gupta Swati, Haidar Sam, Hayes Roger, Ingelse Benno, Ishii-Watabe Akiko, Kaur Surinder, King Lindsay, Laterza Omar, Leung Sheldon, Lévesque Ann, Ma Mark, Petit-Frere Corinne, Pillutla Renuka, Rose Mark, Schultz Gary, Smeraglia John, Swanson Steven, Torri Albert, Vazvaei Faye, Wakelin-Smith Jason, Wilson Amanda, Woolf Eric, Yang Tong-Yuan

机构信息

Biogen Idec Inc., Cambridge, MA, USA.

出版信息

Bioanalysis. 2014;6(24):3355-68. doi: 10.4155/bio.14.283.

DOI:10.4155/bio.14.283
PMID:25534792
Abstract

The 2014 8th Workshop on Recent Issues in Bioanalysis (8th WRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years' editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for Large molecules bioanalysis using LBA and Immunogenicity. Part 1 (Small molecules bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies' Input) were published in the Bioanalysis issues 6(22) and 6(23), respectively.

摘要

相似文献

1
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity).
Bioanalysis. 2014;6(24):3355-68. doi: 10.4155/bio.14.283.
2
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input).2014年生物分析近期问题白皮书:全面深入了解生物分析(第2部分 - 混合配体结合分析/液相色谱 - 质谱联用、电子实验室笔记本及监管机构的投入)
Bioanalysis. 2014;6(23):3237-49. doi: 10.4155/bio.14.279.
3
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1--small molecules by LCMS).
Bioanalysis. 2014;6(22):3039-49. doi: 10.4155/bio.14.265.
4
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).2018年生物分析近期问题白皮书:聚焦混合配体结合分析/液相色谱-质谱联用免疫原性检测及监管反馈(第2部分 - 混合配体结合分析/液相色谱-质谱联用的药代动力学、药效学及抗药物抗体检测以及监管机构对生物分析、生物标志物和免疫原性的意见)
Bioanalysis. 2018 Dec;10(23):1897-1917. doi: 10.4155/bio-2018-0285. Epub 2018 Nov 29.
5
2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs).2017年白皮书:混合LBA/LCMS免疫原性分析方法的兴起(第二部分:混合LBA/LCMS生物治疗药物、生物标志物与免疫原性分析方法以及监管机构的投入)
Bioanalysis. 2017 Dec;9(23):1895-1912. doi: 10.4155/bio-2017-4973. Epub 2017 Dec 5.
6
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).2015年生物分析近期问题白皮书:聚焦新技术与生物标志物(第3部分——LBA、生物标志物与免疫原性)
Bioanalysis. 2015 Dec;7(24):3107-24. doi: 10.4155/bio.15.226. Epub 2015 Dec 4.
7
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies).2015年生物分析近期问题白皮书:聚焦新技术与生物标志物(第2部分 - 混合配体结合分析/液相色谱 - 质谱联用及监管机构的意见)
Bioanalysis. 2015 Dec;7(23):3019-34. doi: 10.4155/bio.15.214. Epub 2015 Dec 2.
8
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs ( - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity).2019年生物分析近期问题白皮书:美国食品药品监督管理局生物分析方法验证指南、国际人用药品注册技术协调会M10生物分析方法验证指南及监管意见( - 关于2018年美国食品药品监督管理局生物分析方法验证指南、2019年国际人用药品注册技术协调会M10生物分析方法验证草案指南以及监管机构对生物分析、生物标志物和免疫原性的意见的建议)
Bioanalysis. 2019 Dec;11(23):2099-2132. doi: 10.4155/bio-2019-0270. Epub 2019 Dec 9.
9
2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers).2017年生物分析近期问题白皮书:生物分析方法验证指南/准则不“科学”吗?(第1部分 - 液相色谱 - 质谱联用:小分子、肽和小分子生物标志物)
Bioanalysis. 2017 Nov;9(22):1807-1825. doi: 10.4155/bio-2017-4975. Epub 2017 Nov 17.
10
2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).2017年生物分析近期问题白皮书:免疫原性指南与生物标志物检测性能的全球视角(第3部分 - 配体结合分析:免疫原性、生物标志物和药代动力学检测)
Bioanalysis. 2017 Dec;9(24):1967-1996. doi: 10.4155/bio-2017-4974. Epub 2017 Dec 5.

引用本文的文献

1
2024 White Paper on Recent Issues in Bioanalysis: Three Way-Cross Validation; Urine Clinical Analysis; Automated Methods; Regulatory Queries on Plasma Protein Binding; Automated Biospecimen Management; ELN Migration; Ultra-Sensitivity Mass Spectrometry ( - Recommendations on Advanced Strategies for Mass Spectrometry Assays, Chromatography, Sample Preparation and BMV/Regulated Bioanalysis - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV).2024年生物分析近期问题白皮书:三方交叉验证;尿液临床分析;自动化方法;血浆蛋白结合的监管问询;自动化生物样本管理;电子实验室笔记本迁移;超灵敏质谱法(- 质谱分析、色谱法、样品制备及生物等效性/法规生物分析的先进策略建议 - 监管机构对法规生物分析/生物等效性的意见)
Bioanalysis. 2025 Mar;17(5):299-337. doi: 10.1080/17576180.2025.2450194. Epub 2025 Jan 25.
2
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).2024年生物分析近期问题白皮书:超越ADA/NAb的免疫原性评估演变;规范的基因组/NGS检测;超敏反应;最小降噪;假阳性范围;现代化疫苗方法;NAb/TAb相关性——基因治疗、细胞治疗、疫苗分子检测和免疫原性的先进策略建议;生物治疗药物免疫原性评估与临床相关性——监管机构对生物治疗药物、基因、细胞和疫苗治疗的免疫原性/技术的意见)
Bioanalysis. 2025 Feb;17(3):105-149. doi: 10.1080/17576180.2024.2439229. Epub 2025 Jan 25.
3
2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA ( - Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) - Regulatory Agencies' Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation).2024年生物分析近期问题白皮书:美国实验室开发检测(LDT)和欧盟体外诊断医疗器械法规(IVDR)的影响;用于高参数流式细胞术的人工智能/机器学习;欧林克技术的兴起;腺相关病毒(AAV)基因疗法的伴随诊断(CDx);多平台整合生物分析;超灵敏抗药物抗体/中和抗体配体结合分析(LBA)(-关于生物标志物、体外诊断/伴随诊断检测(BAV)、基于细胞的检测(CBA)和配体结合分析(LBA)的先进策略建议-监管机构对生物标志物、体外诊断/伴随诊断及生物标志物检测验证的意见)
Bioanalysis. 2025 Feb;17(4):211-248. doi: 10.1080/17576180.2024.2442218. Epub 2025 Jan 25.
4
2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody - Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).2023 年生物分析新问题白皮书:氘代药物;LNP;肿瘤/FFPE 活检;靶向蛋白质组学;小分子共价抑制剂;手性生物分析;远程监管评估;样品核对/监管链-关于质谱、色谱、样品制备最新进展、挑战和解决方案的建议,以及 BMV/监管生物分析-监管机构对监管生物分析/BMV、生物标志物/IVD/CDx/BAV、免疫原性、基因和细胞治疗以及疫苗的投入。
Bioanalysis. 2024;16(9):307-364. doi: 10.1080/17576180.2024.2347153. Epub 2024 May 27.
5
2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( - Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies).2023 年生物分析最新问题白皮书:欧盟 2017/746 法规实施/影响,IVD/CDx/CLIA 批准的检测,高维细胞计数,多重检测技术,LBA 组织分析,疫苗研究终点,基于细胞的生物标志物分析,细胞疗法和疫苗(- 生物标志物、IVD、CDx、基于细胞、流式细胞术、配体结合和酶检测的开发和验证建议;先进的关键试剂策略)。
Bioanalysis. 2024;16(8):179-220. doi: 10.1080/17576180.2024.2340961. Epub 2024 May 22.
6
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization).2023 年生物分析新问题白皮书:ADA 分析的 ISR、dPCR 对 qPCR 的兴起、疫苗分析的国际参考标准、抗 AAV TAb 给药后评估、NanoString 验证、作为金标准的 ELISpot - 基因治疗、细胞治疗、疫苗免疫原性和技术建议;生物治疗药物免疫原性和风险评估;ADA/NAb 分析/报告的协调统一)。
Bioanalysis. 2024 Apr;16(7):77-119. doi: 10.4155/bio-2024-0024. Epub 2024 Feb 22.
7
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.评估抗 Bocizumab 抗体与其他抗 PCSK9 单克隆抗体之间交叉反应性的潜在风险。
BioDrugs. 2019 Oct;33(5):571-579. doi: 10.1007/s40259-019-00375-0.
8
Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography.通过荧光分子断层扫描评估近红外荧光团以研究IL13受体α2抗体的生物分布和肿瘤靶向性。
Oncotarget. 2017 Jul 26;8(34):57231-57245. doi: 10.18632/oncotarget.19569. eCollection 2017 Aug 22.
9
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.双特异性抗体的临床药理学与转化研究方面
Clin Transl Sci. 2017 May;10(3):147-162. doi: 10.1111/cts.12459. Epub 2017 Mar 15.
10
Feasibility of Singlet Analysis for Ligand Binding Assays: a Retrospective Examination of Data Generated Using the Gyrolab Platform.用于配体结合分析的单重分析的可行性:使用 Gyrolab 平台生成的数据的回顾性检查。
AAPS J. 2016 Sep;18(5):1300-1308. doi: 10.1208/s12248-016-9944-8. Epub 2016 Jul 11.